ENANTYUM GRANULATE FOR ORAL SOLUTION
Nonsteroidal anti-inflammatory and antirheumatic drugs.
Ammonium glycyrrhizinate; neohesperidin-dihydrochalcone; quinoline yellow (E104); lemon flavoring; sucrose; colloidal silica hydrates.
Short-term symptomatic treatment of painful affections of mild to moderate intensity, such as acute musculoskeletal pain, dysmenorrhea and dental pain.
CONTRAINDICATIONS / EFF.SECONDAR
Known hypersensitivity to dexketoprofen, or to any other NSAID, or any of the excipients of the product; patients who have developed asthma, bronchospasm, acute rhinitis, urticaria nasal polyps or angioneurotic edema after exposure to substances with a similar mechanism of action (e.g. acetylsalicylic acid, or other NSAIDs); patients with known photoallergic or phototoxic reactions during treatment with ketoprofen or -fibrates; patients with a history of gastrointestinal bleeding or perforation related to previous NSAID therapy; patients with recurrent peptic ulcer / gastrointestinal bleeding in progress or a history of recurrent peptic ulcer / gastrointestinal bleeding (two or more distinct episodes of documented ulceration or bleeding); patients with chronic dyspepsia or suspected peptic ulcer / bleeding; patients who have other bleeding or clotting disorders; patients with Crohn's disease or ulcerative colitis; patients with severe heart failure; patients with moderate to severe renal failure; patients with severe liver failure; patients with hemorrhagic diathesis and other coagulation disorders; patients with severe dehydration (caused by vomiting, diarrhea or insufficient fluid intake); during the third trimester of pregnancy and breastfeeding.
Adults: based on the nature and intensity of pain, the recommended dose is generally 12,5 mg every 4-6 hours or 25 mg every 8 hours. The total daily dose should not exceed 75 mg. Side effects can be minimized by using the lowest effective dose for the time strictly necessary to eliminate the symptoms. The medicine is indicated only for short-term treatments and administration should be limited to the symptomatic period only. The concomitant administration of food delays the rate of absorption of the drug, therefore, in case of acute pain, it is recommended to administer the drug at least 15 minutes before meals. Elderly: in elderly patients it is recommended to start therapy with the lowest therapeutic dose (50 mg the total daily dose). The dosage can be increased in order to reach that recommended for the adult only after a good tolerability has been ascertained. Because of the risk profile, the elderly must be checked with particular attention. Hepatic dysfunction: patients with mild to moderate hepatic dysfunction should start therapy at reduced doses (50 mg total daily dose) under close medical supervision. The drug should not be used in patients with severe liver dysfunction. Renal dysfunction: in patients with mild renal impairment the initial dosage should be reduced to 50 mg total daily dose. The drug should not be used in patients with moderate to severe renal impairment. Children and adolescents: the product has not been studied in children and adolescents. Therefore, as no safety and efficacy data are available, the product should not be used in adolescent children.
This medicine does not require any special storage precautions.
The safety of use in children and adolescents has not been established. Use with caution in patients with a history of allergic conditions. Avoid concomitant use of the drug with other NSAIDs. Side effects can be minimized by using the lowest effective dose for the time strictly necessary to eliminate symptoms. Potentially fatal bleeding, ulceration or gastrointestinal perforation have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or prior medical history. serious gastrointestinal events, discontinue therapy. The risk of gastrointestinal bleeding, ulceration or perforation increases with increasing NSAID dosage in patients with previous ulcer, especially if complicated by bleeding or perforation and in the elderly. The elderly have a higher frequency of adverse reactions to NSAIDs. Start treatment with the lowest available dose. Before starting the treatment, it is necessary to investigate previous esophagitis, gastritis and / or peptic ulcers and make sure of their total recovery. Monitor patients with gastrointestinal symptoms or a history of gastrointestinal disease. Administer NSAIDs with caution to patients with a history of gastrointestinal disease, as these conditions can be exacerbated. Concomitant use of protective agents should be considered for these patients and for patients receiving a low concomitant dose of aspirin or other medications that may increase gastrointestinal risk. Caution is advised in patients who are co-administered with drugs that may increase the risk of ulceration or bleeding. Use with caution in patients with impaired renal function. In these patients the use of NSAIDs can cause deterioration of kidney function, fluid retention and edema. Caution should be exercised, for an increased risk of nephrotoxicity, even in patients on diuretic therapy or at risk of developing hypovolemia. During treatment, adequate fluid intake must be guaranteed to prevent dehydration and the risk of renal toxicity. The product may cause an increase in blood urea nitrogen and creatininemia. Side effects affecting the kidney may occur which can lead to glomerular nephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure. Elderly patients are at the greatest risk of renal failure. Caution should be exercised in patients with hepatic impairment. It can cause small transient increases in some liver function parameters, and also significant increases in GOT and GPT. In the event of a significant increase in these parameters, discontinue therapy. Elderly patients are more exposed to risk of liver function failure. Appropriate monitoring is required for patients with a history of hypertension and / or mild to moderate heart failure. Particular caution should be exercised in cardiac patients, especially if with a history of heart failure since there is an increased risk of heart failure, as fluid retention and edema have been reported in association with the use of NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs (especially high dosages and protracted therapies) may be associated with a slight increase in the risk of arterial thrombotic events. There are insufficient data to exclude this risk for dexketoprofenetrometamol. Therefore patients with uncontrolled hypertension, congestive heart failure, ascertained ischemic heart disease, peripheral arterial disease and / or cerebrovascular disease should only be treated with dexketoprofen trometamol after careful consideration.Pay attention before starting long-term treatment in patients with factors of risk for cardiovascular diseases. All non-selective NSAIDs are able to inhibit platelet aggregation and prolong bleeding time by inhibiting prostaglandin synthesis. The use of dexketoprofen trometamol is therefore not recommended in patients receiving another therapy that interferes with hemostasis, such as warfarin or other coumarin or heparin. Elderly patients, in general, are the most exposed to the risk of insufficiency of cardiovascular function. Serious skin reactions (some of them fatal) have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients seem to be at a higher risk: the onset of reactions occurs, in most cases, within the first month of treatment. At the first appearance of skin rash, mucosal lesions or any other symptoms of hypersensitivity, discontinue therapy. Particular caution is required in patients with: congenital anomalies of porphyrin metabolism; dehydration; immediately after an important surgery. If long-term therapy with dexketoprofen is deemed necessary, liver, kidney and blood count should be checked regularly. Serious acute hypersensitivity reactions have been observed in very rare cases. At the first manifestation of severe hypersensitivity reactions, stop treatment. In exceptional cases chickenpox can be associated with infectious complications of the skin and soft tissues. To date, a role of NSAIDs in the aggravation of these infections cannot be excluded, so it is advisable to avoid the use of the drug in patients with chicken pox. Administer the medicine with caution to patients suffering from hematopoietic disorders, systemic lupus erythematosus or mixed connective tissue disease. Dexketoprofen can mask symptoms of infectious diseases. This medicine contains sucrose.
The following interactions are characteristic of nonsteroidal anti-inflammatory drugs (NSAIDs) in general. >> Associations not recommended. Other NSAIDs, including high doses of salicylates (> = 3 g / day): co-administration of multiple NSAIDs may increase the risk of ulceration and gastrointestinal bleeding due to a synergistic effect. Anticoagulants: NSAIDs may potentiate the effects of anticoagulants, such as warfarin, due to the high plasma protein binding of dedeketketoprofen, inhibition of platelet function and damage to the gastro-duodenal mucosa. If association cannot be avoided, rigorous clinical observation and monitoring of laboratory parameters are required. Heparin: increased risk of bleeding (due to inhibition of platelet function and gastrointestinal damage to the mucosa). If association cannot be avoided, rigorous clinical observation and monitoring of laboratory parameters are required. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding. Lithium (described with many NSAIDs): NSAIDs increase blood lithium levels with the risk of reaching toxic values (decreased renal lithium excretion) .This parameter therefore requires careful monitoring at the beginning, during adjustment and at the end of the treatment. with dexketoprofen. Methotrexate when used in high doses (> = 15 mg / week): increased haematological toxicity of methotrexate due to a decrease in its renal clearance, generally with NSAIDs. Idantoins and sulfonamides: the toxic effects of these substances can be potentiated. >> Associations requiring caution. Diuretics, ACE inhibitors, aminoglycoside antibiotics and angiotensin II receptor antagonists: dexketoprofen can reduce the effect of diuretics and antihypertensive drugs. In some patients with impaired renal function (e.g. dehydrated patients or elderly patients with impaired renal function), the co-administration of agents that inhibit cyclooxygenase and ACE inhibitors, angiotensin II receptor antagonists or aminoglycoside antibiotics may cause further deterioration of renal function, usually reversible. In the event of a concomitant prescription of dexketoprofen and a diuretic, it is essential to ensure adequate hydration of the patient and check renal function both at the beginning of the treatment and periodically thereafter. Co-administration of the drug and potassium-sparing diuretics can cause hyperkalemia. Blood potassium concentrations should be monitored. Methotrexate when used in low doses (<15 mg / week): increased haematological toxicity of methotrexate due to a decrease in its renal clearance generally caused by anti-inflammatory drugs. Check blood counts weekly for the first few weeks of combination therapy. Increase surveillance in elderly patients and in the presence of even mild renal failure. Pentoxifylline: increased risk of bleeding. Monitor carefully and check the bleeding time more frequently. Zidovudine: increased risk of red cell line toxicity due to action on reticulocytes, with possible onset of severe anemia one week after starting treatment with NSAIDs. Perform complete blood count and reticulocyte control every 7-14 days during treatment with NSAIDs. Sulphonylureas: NSAIDs can increase the hypoglycaemic effect of sulphonylureas by saturation of plasma protein binding sites. >> Association to evaluate carefully. Beta-blockers: treatment with NSAIDs can decrease their antihypertensive effect due to the inhibition of the synthesis of prostaglandins. Cyclosporine and tacrolimus: NSAIDs can enhance nephrotoxicity due to the effects mediated by renal prostaglandins. During therapy, check kidney function. Thrombolytics: increased risk of bleeding. Anti-platelet agents and SSRIs (selective serotonin reuptake inhibitors): increased risk of gastrointestinal bleeding. Probenecid: may increase the plasma concentrations of dexketoprofen; this interaction may be due to an inhibitory mechanism at the level of renal tubule secretion and glucuronoconjugation and requires an adjustment of the dose of dexketoprofen. Cardioactive glycosides: NSAIDs can increase plasma concentrations of glycosidicardioactive agents. Mifepristone: there is a theoretical risk that prostaglandin synthetase inhibitors may alter the efficacy of mifepristone. Limited evidence suggests that concomitant administration of NSAIDs on the same day as prostaglandin administration does not adversely affect the effects of mifepristone or prostaglandins on cervical maturation or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy. Quinolones: Animal studies indicate that high doses of quinolone antibiotics in combination with NSAIDs may increase the risk of seizures.
Adverse reactions, probably related to dexketoprofen trometamol, which occurred during clinical studies and after the marketing of the drug granules, are grouped by system and listed in order of frequency. The plasma C max levels of dexketoprofen in the granule formulation are higher than those reported for the tablet formulation, therefore a potential increase in the risk of adverse events (gastrointestinal) cannot be excluded. Blood and lymphatic system disorders. Very rare: neutropenia, thrombocytopenia. Immune system disorders. Very rare: anaphylactic reactions, including anaphylactic shock; not known: laryngeal edema Metabolism and nutrition disorders. Rare: anorexia. Psychiatric disorders. Uncommon: insomnia; anxiety. Nervous system disorders. Uncommon: headache, dizziness, somnolence rare: paraesthesia, syncope. Eye disorders. Very rare: blurred vision Ear and labyrinth disorders. Uncommon: dizziness; very rare: tinnitus. Cardiac pathologies. Uncommon: palpitations; very rare: tachycardia. Vascular pathologies. Uncommon: hot flashes; rare: hypertension; very rare: hypotension. Respiratory, thoracic and mediastinal disorders. Rare: bradypnea; very rare: bronchospasm, dyspnoea. Gastrointestinal pathologies. Common: nausea and / or vomiting, abdominal pain, diarrhea, dyspepsia; uncommon: gastritis, constipation, dry mouth, flatulence; rare: peptic ulcer, hemorrhage or perforation from peptic ulcer; very rare: pancreatitis. Hepatobiliary disorders Rare: liver injury; very rare: hepatocellular damage; not known: hepatitis. Skin and subcutaneous tissue disorders. Uncommon: rash rare: urticaria, acne, increased sweating; very rare: Steven Johnson syndrome, toxic epidermal necrolysis (Lyell syndrome), angioedema, facial edema, photosensitivity reaction, pruritus. Musculoskeletal and connective tissue disorders. Rare: back pain. Renal and urinary disorders. Rare: polyuria; very rare: nephritis or nephrotic syndrome; not known: acute renal failure. Reproductive system and breast disorders. Rare: menstrual disorders. prostate disorders. Systemic and administration site disorders. Uncommon: fatigue, pain, asthenia, chills, feeling unwell; rare: peripheral edema. Diagnostic tests. Rare: abnormalities in liver function tests. The most commonly observed undesirable effects are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding can occur, sometimes fatal especially in the elderly. Following administration, nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported. Gastritis has been reported less frequently. Edema, hypertension and heart failure have been reported in association with NSAID therapy. The results of clinical trials and epidemiological data suggest that the use of some NSAIDs (especially at high doses and for long periods) may be associated with a slight increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). As with other NSAIDs, the following side effects may appear: aseptic meningitis, which can occur predominantly in patients with systemic lupus erythematosus or mixed connective tissue disease; hematological reactions (purpura, aplastic and hemolytic anemia, and rarely agranulocytosis and bone marrow hypoplasia).
PREGNANCY AND BREASTFEEDING
The medicine is contraindicated in pregnancy and during breastfeeding. Inhibition of prostaglandin synthesis can have negative effects on pregnancy and / or on the development of the embryo or fetus. Results of epidemiological studies suggest an increased risk of spontaneous diabetic and cardiac malformation and gastroschisis after the use of an inhibitor of the synthesis of prostaglandins in the early stages of pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. In addition, an increase in the incidence of various malformations, including cardiovascular malformations, has been reported in animals. to which prostaglandin synthesis inhibitors were administered during the organogenetic period. However, animal studies with dexketoprofen trometamol did not show reproductive toxicity. During the first and second trimester of pregnancy, dexketoprofen trometamol should only be administered in strictly necessary cases. Sedexketoprofen trometamol is used by a woman awaiting conception or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); renal dysfunction, which can progress to renal failure with oligohydramnios; the mother and the newborn, at the end of pregnancy, to: possible prolongation of the bleeding time, and antiplatelet effect that can also occur at very low dosages; inhibition of uterine contractions, with consequent delay or prolongation of labor. The use of the medicine can damage female fertility and it is not recommended to be administered to women who wish to become pregnant. In the case of women with conception difficulties or who are undergoing tests for infertility, consider discontinuing the administration of dexketoprofen trometamol. It is not known whether dexketoprofen is excreted in breast milk. The drug is contraindicated during breastfeeding.
Delivery is made within 24-72 working hours, Monday to Friday, excluding holidays.
WARNING! In times of high turnout, such as Black Friday, Christmas or Sales, delivery times may increase.
Shipping costs are calculated automatically during the order phase.
- EXPRESS shipping 24-72 working hours
For orders over € 40,00 shipping is free. For orders less than € 40,00 the following applies:
- - € 0,00 - € 9,99: € 6,99
- - € 10,00 - € 19,99: € 5,99
- - € 20,00 - € 29,99: € 4,99
- - € 30,00 - € 39,99: € 3,99
- - € 40,00 and up: € 0,00
- Cash on delivery
For orders over € 70,00 shipping is € 3.99. For orders less than € 70,00 the following applies:
- - € 0,00 - € 9,99: € 10,98
- - € 10,00 - € 19,99: € 9,98
- - € 20,00 - € 29,99: € 8,98
- - € 30,00 - € 39,99: € 7,98
- - € 40,00 - € 49,99: € 6,98
- - € 50,00 - € 59,99: € 5,98
- - € 60,00 - € 69,99: € 4,98
- - € 70,00 and up: € 3,99
WARNING! If you want to pay cash on delivery, when ordering you need to select the item twice, otherwise the total amount will be added € 3,99 for the service.
- Delivery by 12.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 12.00 on the following day, excluding Saturday and Sunday.
- € 10.99
- Delivery by 10.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 10.00 on the following day, excluding Saturday and Sunday.
- € 15.99
- € 7.98
Farmaveloce will deliver your order to the address of your choice throughout Italy, including the islands.
All orders with EXPRESS Shipping are entrusted to the Courier BRT, GLS, UPS, DHL, FedEx & TNT, Poste Italiane.
farmaveloce.com collects some Personal Data from its Users.
Owner of the Data Privacy
Via Savelli, 10 35129 Padua (Italy)
Email address of the owner: ROAD@ farmaveloce.com
The site: farmaveloce.com
Types of data collected
Among the Personal Data collected, independently or through third parties, there are: Cookies, Data of
use, name, surname, telephone number, VAT number, address, country, postcode, various types
of data, city and tax code.
Full details on each type of data collected are provided in the dedicated sections of this
Personal Data can be freely provided by the User or, in the case of Usage Data,
collected automatically when using the site.
Unless otherwise specified, all data requested by the site are mandatory.
If the User refuses to communicate them, it may be impossible for farmaveloce.com to provide the Service.
In cases where farmaveloce.com indicates some Data as optional, Users are free to
refrain from communicating such Data, without this having any consequence on the availability of the
Service or its operation.
Users who have doubts about which data are mandatory are encouraged to contact
of third party services used by the site, unless otherwise specified, has the purpose of providing the Service
requested by the User, in addition to the additional purposes described in this document and in the Cookie
Policy, if available.
The User assumes responsibility for the Personal Data of third parties obtained, published or shared
through farmaveloce.com and guarantees to have the right to communicate or disseminate them, freeing
the Owner from any liability to third parties.
Mode and place of processing of data collected
Mode of treatment
The Data Controller adopts the appropriate security measures to prevent access, disclosure, the
unauthorized modification or destruction of Personal Data.
The treatment is carried out using IT and / or telematic tools, with methods
organizational and with logic strictly related to the purposes indicated. In addition to the owner, in some
cases, other subjects involved in the organization of the site (staff
administrative, commercial, marketing, legal, system administrators) or external subjects
(such as third party technical service providers, couriers, hosting providers, IT companies,
communication agencies) also appointed, if necessary, Data Processors by the
Holder. The updated list of Managers can always be requested from the Data Controller
Legal basis of the processing
The Holder processes Personal Data relating to the User in the event one of the following conditions exists:
• the User has given consent for one or more specific purposes; Note: in some systems
the Data Controller can be authorized to process Personal Data without the existence of the
User's consent or another of the legal bases specified below, until
the User does not object ("opt-out") to this treatment. This however is not applicable if
the processing of Personal Data is regulated by European legislation on
protection of personal data;
• processing is necessary for the execution of a contract with the User and / or for the execution of
• processing is necessary to fulfill a legal obligation to which the Data Controller is subject;
• processing is necessary for the performance of a public interest task or for
the exercise of public powers with which the Data Controller is invested;
• the processing is necessary for the pursuit of the legitimate interest of the owner or third parties.
In any case, it is always possible to request the Data Controller to clarify the concrete legal basis of each
treatment and in particular to specify whether the treatment is based on the law, provided for by a
contract or necessary to conclude a contract.
The data are processed at the owner's operating offices and in any other place where the parties involved
in the treatment are localized.
For more information, contact the owner.
The User's Personal Data may be transferred to a country other than the one in which the User
is situated. To obtain further information on the place of treatment, the User can refer to
to the section on details on the processing of Personal Data.
The User has the right to obtain information regarding the legal basis for the transfer of Data to
outside the European Union or to an international international law organization
public or consisting of two or more countries, such as the UN, as well as on the measures of
security adopted by the Data Controller to protect the Data.
The User can check whether one of the transfers described above takes place by examining the section
of this document relating to details on the processing of Personal Data or request information from the
Owner by contacting him at the ends shown at the beginning.
The Data are processed and stored for the time required by the purposes for which they were collected.
• Personal Data collected for purposes related to the execution of a contract between the Owner and
the User will be held until the execution of this contract is completed.
• Personal Data collected for purposes related to the legitimate interest of the Owner will be
held until the satisfaction of this interest. The User can get further
information on the legitimate interest pursued by the Data Controller in the relevant sections of
this document or by contacting the owner.
When the treatment is based on the User's consent, the Data Controller can keep Personal Data
longer until such consent is revoked. In addition, the owner could be
obliged to keep Personal Data for a longer period in compliance with an obligation to
law or by order of an authority.
At the end of the retention period, Personal Data will be deleted. Therefore, at the expiration of
this term the right of access, cancellation, rectification and the right to data portability
they can no longer be exercised.
The use of the data collected
User data are collected to allow the owner to provide their services, as well as for
following purposes: Statistics, Interaction with external social networks and platforms, Access to
account on third party services and Contact the User.
To obtain further detailed information on the purposes of the processing and on Personal Data
concretely relevant for each purpose, the User can refer to the relevant sections of
Facebook permissions requested by la farmaveloce.com
Unless otherwise specified
The site may request some Facebook permissions that allow it to perform actions with the account
User's Facebook and to collect information, including Personal Data, from it. This service
allows the site to connect with the User's account on the Facebook social network, provided by
For more information on the following permissions, refer to the documentation of the
The required permits are as follows:
The basic information of the User registered on Facebook which normally includes the following
Data: id, name, image, gender and localization language and, in some cases, the "Friends" of
Facebook. If the User has made publicly available additional data, the same will be available.
Access to private data
Allows access to the User's and friends' private data.
Access to friend lists
Provides access to the lists of friends that the User has created.
Add or edit photos.
Allows the app to add or edit User videos.
Provides access to the list of events in which the User participates.
I like it
Provides access to the list of all the pages that the User has marked with the Like.
Provides access to the User's website.
Details on the processing of Personal Data
The Personal Data are collected for the following purposes and using the following services:
Access to accounts on third party services
This type of service allows the site to collect data from your accounts on third party services and
perform actions with them.
These services are not activated automatically, but require express authorization
Access to the Facebook account (farmaveloce.com)
This service allows the site to connect with the User's account on the social network
Facebook, provided by Facebook, Inc.
Permissions asked: Access to private data, Access to friend lists, Upload photos, Upload of
Videos, Events, Likes and Website.
Contact the user
By filling in the contact form with their Data, the User consents to their use for
respond to requests for information, quotes, or any other kind indicated
from the form header.
Personal data collected: post code, city, tax code, surname, address, country, name, number of
telephone, VAT number and various types of data.
Interaction with external social networks and platforms
This type of service allows you to interact with social networks, or with other platforms
external, directly from the pages of the site
The interactions and information acquired from the site are in any case subject to the settings
User privacy related to each social network.
In the event that an interaction service with social networks is installed, it is possible that, too
if Users do not use the service, it collects traffic data relating to the pages in
which it is installed on.
Like button and social widgets for Facebook (Facebook, Inc.)
The "Like" button and Facebook social widgets are social interaction services
Facebook network, provided by Facebook, Inc.
Personal Data collected: Cookies and Usage Data.
The services contained in this section allow the Data Controller to monitor and
analyze traffic data and are used to keep track of User behavior.
Google Analytics (Google Inc.)
Google Analytics is a web analysis service provided by Google Inc. ("Google"). Google uses i
Personal data collected for the purpose of tracking and examining the use of farmaveloce.com,
compile reports and share them with other services developed by Google.
Google may use the Personal Data to contextualise and personalize the advertisements of the
own advertising network.
Personal Data collected: Cookies and Usage Data.
More information on Personal Data
Selling goods and services online
The Personal Data collected is used for the provision of services to the User or for the sale of
products, including payment and possible delivery. Personal Data collected to perfect the
payment may be those relating to the credit card, the current account used for the
bank transfer or other expected payment instruments. Payment data collected by
farmaveloce.com depend on the payment system used.
Users may exercise certain rights with reference to the Data processed by the Data Controller.
In particular, the User has the right to:
• withdraw consent at any time. The User can withdraw consent to the treatment
of their Personal Data previously expressed.
• object to the processing of their data. The user can object to the processing of their data
when it occurs on a legal basis other than consent. Further details on the law
of opposition are indicated in the section below.
• access their Data. The User has the right to obtain information on the Data processed by the
Holder, on certain aspects of the treatment and to receive a copy of the Data processed.
• verify and request correction. The User can verify the correctness of their Data
and request its updating or correction.
• obtain the limitation of the treatment. When certain conditions are met,
the User can request the limitation of the processing of their Data. In this case the Owner
will not process the Data for any other purpose other than their conservation.
• obtain the cancellation or removal of their Personal Data. When they recur
certain conditions, the User can request the deletion of their Data by the
• receive your data or have it transferred to another holder. The User has the right to receive i
own Data in structured format, commonly used and readable by automatic device and, where
technically feasible, to obtain the transfer without hindrance to another owner. This
provision is applicable when the Data are processed with automated tools and the
processing is based on the User's consent, on a contract of which the User is a party or on
contractual measures connected to it.
• propose a complaint. The User can lodge a complaint with the supervisory authority of the
protection of personal data competent or to act in court.
Details on the right of opposition
When Personal Data are processed in the public interest, in the exercise of public powers referred to
the Owner is invested or to pursue a legitimate interest of the Owner, the Users have
right to object to processing for reasons related to their particular situation.
Users are reminded that if their data were processed for direct marketing purposes,
can oppose the treatment without giving any reason. To find out if the owner deals
data for direct marketing purposes Users can refer to the respective sections of
How to exercise the rights
To exercise the User's rights, Users can address a request to the ends of
contact of the Owner indicated in this document. Requests are filed free of charge and
processed by the Owner as soon as possible, in any case within a month.
Additional information on treatment
Defense in court
The User's Personal Data may be used by the Owner in court or in stages
preparatory to its possible establishment for the defense against abuse in the use of
farmaveloce.com or related Services by the User.
The User declares to be aware that the Data Controller may be obliged to reveal the Data
by order of the public authorities.
farmaveloce.com could provide the User with additional and contextual information
concerning specific Services, or the collection and processing of Personal Data.
Log System and Maintenance
For needs related to the operation and maintenance of the site and any third party services from
it used could collect system logs, that is files that record the interactions and that
they may also contain Personal Data, such as the User IP address.
Information not contained in this Policy
Further information in relation to the processing of Personal Data may be requested in
at any time to the Data Controller using the contact details.
Response to "Do Not Track" requests
The site does not support "Do Not Track" requests.
To find out if any third-party services used support them, the User is invited to
consult the respective privacy policies.
any time giving information to Users on this page and, if possible, on the site
as well as, if technically and legally feasible, by sending a notification to Users through one
of the contact details held by the Owner. Therefore, please consult regularly
this page, referring to the date of last modification indicated at the bottom.
If the changes affect treatments whose legal basis is consent, the Owner
will collect the User's consent again, if necessary.
Definitions and legal references
Personal Data (or Data)
It constitutes personal data any information that, directly or indirectly, also in
link with any other information, including an identification number
personal, makes a natural person identified or identifiable.
Data of Use
This is the information collected automatically through the site (also by party applications
third parties integrated into the site), including: IP addresses or domain names of the computers used
by the User who connects with the site, the addresses in URI (Uniform Resource Identifier) notation,
the time of the request, the method used to forward the request to the server, the file size
obtained in response, the numeric code indicating the status of the response from the server (successful, error,
etc.) the country of origin, the characteristics of the browser and operating system used by the
visitor, the various temporal connotations of the visit (for example the time spent on
each page) and the details of the itinerary followed within the Application, with
particular reference to the sequence of the pages consulted, to the parameters relating to the system
operating environment and the IT environment of the User.
The individual who uses the site which, unless otherwise specified, coincides with the interested party.
The natural person to whom the Personal Data refers.
Data Processor (or Manager)
The natural person, legal entity, public administration and any other entity that processes data
Data Controller (or Owner)
The natural or legal person, public authority, service or other body which, individually or
together with others, it determines the purposes and means of the processing of personal data and the tools
adopted, including the security measures relating to the operation and use of
farmaveloce.com. Unless otherwise specified, the Data Controller is the
owner of farmaveloce.com.
farmaveloce.com (or this Application)
The hardware or software tool through which the Personal Data of the
The service provided by the site as defined in the relative terms (if any) on this
site / application.
European Union (or EU)
Unless otherwise specified, any reference to the European Union contained in this
document is intended to be extended to all current member states of the European Union and Space
Small portion of data stored in the User's device.
This privacy statement is drawn up on the basis of multiple legislative systems, including articles 13 and 14 of the Regulation (EU) 2016 / 679.
Unless otherwise specified, this privacy statement only concerns the site.
RIGHT OF WITHDRAWAL
Deadline for withdrawal
The Consumer has a period of fourteen days to withdraw from the contract without having to provide any reason.
The aforementioned term starts:
a) if a service is offered from the day of the conclusion of the contract
b) in the case of sale of a product, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the goods or:
• in the case of multiple goods ordered by the Consumer through a single order and delivered separately, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last good;
• in the case of delivery of an asset consisting of lots or multiple pieces, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last lot or piece;
• in the case of contracts for the periodic delivery of goods during a certain period of time, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the first asset.
Obligations of the pharmacy The pharmacy, following the withdrawal of the consumer:
• immediately communicates to the Consumer a confirmation of receipt, on a durable medium, of the Withdrawal exercised;
• reimburses the same all payments received, not including delivery costs, without undue delay and in any case within fourteen days from the day of the communication of the Right of Withdrawal.
• the pharmacy reimburses using the same means of payment used by the Consumer, unless otherwise agreed after payment.
Obligations for the Consumer
The shipping costs for the return of the products received must be paid by the Consumer, which must be shipped within fourteen days from the date on which he communicated his decision to withdraw from the contract (the deadline is respected if the Consumer returns the goods before the expiry of the fourteen day period).
The substantial integrity of the asset is an essential condition for exercising the right of withdrawal. The Product must therefore be kept with normal diligence and returned intact, complete in all its parts, fully functional and free of signs of wear or dirt.
Exceptions to the Right of Withdrawal - products for which the application of the Right of Withdrawal is excluded
The right of withdrawal cannot be exercised:
a) in case of purchase of medicines and medical devices
b) supply of food, drinks or other goods intended for current consumption in the family and physically supplied by a professional in frequent and regular rounds to the consumer's home, residence or workplace
c) in the case of purchases of less than 50 euros (unless the total consideration that the Consumer must pay regardless of the amount of the individual contracts exceeds 50 euros);
d) in the case of a contract for a service after the complete provision of the service if the execution of the contract began with the express agreement of the Consumer;
e) in case of supply of goods made to measure or clearly personalized;
f) in the event of the supply of goods which are liable to deteriorate or expire rapidly;
g) in the case of the supply of sealed goods that do not lend themselves to be returned for reasons of hygiene or connected to the protection of health and have been opened after delivery;
h) in case of supply of goods which after delivery are by their nature inseparably mixed with other ben.
In the event of a lack of conformity, or delivery of goods that present defects or defects or are different from that provided in the sales contract, i.e. unsuitable for the use for which a good of the same is usually used
type, which differs from the description published on the site or which does not manifest the promised qualities, the provisions of the Legal Guarantee as per articles 128 and following of Legislative Decree 205/2006 (Consumer Code).
Any breakdowns or malfunctions caused by accidental events or by Customer's liability or by a use of the product not in accordance with its intended use and / or as foreseen in the technical documentation attached to the product are excluded from the scope of the Legal Guarantee.
The pharmacy is liable when the lack of conformity occurs within two years from the delivery of the goods, unless there is a conventional guarantee beyond this term. In case of sale of used goods, the guarantee referred to in the previous paragraph may be limited to a period of time however
not less than one year.
The Consumer is required to report the defect or defect to me quickly within two months of discovery (unless the sector has recognized or concealed the existence of the defect).
It is assumed that the defects of conformity that occur within six months of delivery of the goods already existed on that date, unless this hypothesis is incompatible with the nature of the asset or with the nature of the defect of
The direct action to assert defects not maliciously concealed by the seller is prescribed within twenty-six months from the delivery of the goods (the Consumer who is agreed for the execution of the contract can nevertheless always assert the rights referred to in this article provided that the lack of conformity has been reported within two months of discovery and before the expiry of the two years from delivery).
In the event of a lack of conformity, the Consumer can request, at no cost (including shipping), the restoration by repair or replacement, at his choice, unless the remedy is objectively impossible or excessively expensive compared to the other.
The above remedy is to be considered excessively expensive if it imposes unreasonable costs on the store compared to the other, taking into account:
a) the value that the asset would have if there were no lack of conformity;
b) the extent of the lack of conformity;
c) the possibility that the alternative remedy can be tried without significant inconvenience for the Consumer.
Repairs or replacements will be carried out within a reasonable time from the request and must not cause significant inconvenience to the Consumer, taking into account the nature of the goods and the purpose for which it was purchased.
The Consumer can request, at his choice, a reasonable reduction in the price or termination of the contract if one of the following situations occurs:
a) repair and replacement are impossible or excessively expensive;
b) the seller did not replace within a reasonable time;
c) the replacement or repair previously carried out has caused significant inconvenience to the Consumer.
The use of the asset is taken into account when determining the amount of the reduction or the amount to be returned.
After reporting the lack of conformity, the seller can offer the consumer any other available remedy, with the following effects:
a) if the Consumer has already requested a specific remedy, the seller remains obliged to implement it, with the necessary consequences regarding the commencement of the appropriate term for repairs or replacements, unless the Consumer accepts the proposed alternative remedy;
b) if the Consumer has not already requested a specific remedy, the Consumer must accept the proposal or reject it by choosing another remedy pursuant to this article.
A slight lack of conformity, for which it has not been possible or is excessively burdensome to carry out the remedies of repair or replacement, does not give the right to terminate the contract.
The Legal Guarantee is limited to purchases made by Consumers. As regards subjects other than Consumers, the provisions of the Consumer Code apply to Articles 1490 et seq.
Conventional Manufacturer Warranty
The products sold on the Site may, depending on their nature, be covered by a conventional warranty issued by the manufacturer ("Conventional Warranty"). The customer can only enforce this guarantee against the manufacturer. The duration, the extension, also territorial, the conditions and methods of use, the types of damage / defects covered and any limitations of the Conventional Warranty depend on the individual manufacturer and are indicated in the so-called warranty certificate contained in the product packaging. The Conventional Guarantee is voluntary in nature and does not add, replace, limit or prejudice or exclude the Legal Guarantee.
Payment and security
Your payment information is processed securely. We do not store credit card details nor do we have access to your credit card information.
Lactoferrin 200 Mg Immuno 30 Stickpack
LATTOFERRINA 200 IMMUNO is a food supplement of lactoferrin. Lactoferrin is a multifunctional protein with antimicrobial and antiviral properties